Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for CapsoVision Inc. (CV:NASDAQ), powered by AI.
CapsoVision Inc. is currently trading at $7.19. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for CapsoVision Inc. on Alpha Lenz.
View CapsoVision Inc.'s valuation metrics on Alpha Lenz.
“CapsoVision Inc.'s ROE is 43.6%. Explore profitability and growth together.”
Ask for details →CapsoVision Inc. is a commercial-stage medical technology company specializing in the development of advanced imaging and artificial intelligence-driven solutions for capsule endoscopy. Its core innovations are designed to empower physicians and streamline clinical operations by enhancing the detection and diagnosis of abnormalities within the gastrointestinal tract. CapsoVision’s flagship product, the CapsoCam Plus®, is a small bowel capsule endoscope that offers a 360° panoramic lateral view—a unique feature in the field—alongside a wire-free design for enhanced patient comfort. The company’s offerings also include products and cloud-based services such as CapsoCloud® for efficient image review and analysis, and solutions for colon visualization and polyp detection. CapsoVision addresses critical needs in the healthcare sector, particularly for gastrointestinal specialists and hospital systems seeking noninvasive diagnostic tools. Its role in the market is defined by its commitment to improving patient care, driving innovation in medical devices, and supporting better clinical outcomes through cutting-edge technology. Annual revenue is reported in the low eight figures, with a growing presence in the medical equipment manufacturing and diagnostic equipment industries.
“CapsoVision Inc.'s ROE is 43.6%. Explore profitability and growth together.”
Ask for details →CapsoVision Inc. (ticker: CV) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 90 employees.
The current price is $7.19 with a P/E ratio of -x and P/B of -x.
ROE is 43.55% and operating margin is -188.25%. Annual revenue is $14M.